Exelixis (EXEL) EBIT Growth (3y) (2013 - 2026)

Exelixis (EXEL) EBIT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Exelixis 14.38 Bn 13.60 Bn 590.86 Mn 105.81%

Historic Data

Download Data
DateValue
Apr 3, 2026 105.81%
Jan 2, 2026 90.31%
Oct 3, 2025 42.00%
Jul 4, 2025 36.65%
Apr 4, 2025 30.93%
Jan 3, 2025 -4.62%
Sep 27, 2024 38.14%
Jun 28, 2024 30.90%
Mar 29, 2024 103.24%
Dec 29, 2023 49.87%
Sep 29, 2023 25.53%
Jun 30, 2023 1.01%
Mar 31, 2023 -18.27%
Dec 30, 2022 -37.89%
Sep 30, 2022 -10.60%
Jul 1, 2022 -3.10%
Apr 1, 2022 -0.52%
Dec 31, 2021 19.00%
Oct 1, 2021 -25.57%
Jul 2, 2021 12.77%